Drugs & Targets FDA publishes final guidance on drug development for AML October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on characterizing, collecting, and reporting immune-mediated adverse reactions October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on tissue agnostic drug development in oncology October 21, 2022Vol.48 No.38
Clinical Roundup New data show more than 2.5M U.S. youth use e-cigarettes October 07, 2022Vol.48 No.36
Drugs & Targets FDA grants accelerated approval to Lytgobi for cholangiocarcinoma October 07, 2022Vol.48 No.36
ODAC nixes three cancer drug indications, citing dose uncertainty September 30, 2022Vol.48 No.35By Jacquelyn Cobb
Conversation with The Cancer Letter FDA spells out new systematic approach to giving out–and taking away–accelerated approvals in oncology September 23, 2022Vol.48 No.34By Paul Goldberg
Drugs & Targets FDA approves Retevmo for locally advanced or metastatic RET fusion-positive solid tumors, NSCLC September 23, 2022Vol.48 No.34
Drugs & Targets FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin for localized pediatric solid tumors September 23, 2022Vol.48 No.34
Drugs & Targets FDA issues safety alert for squamous cell carcinoma and various lymphomas in scar tissue around breast implants September 16, 2022Vol.48 No.33
